Loading stock data…
Outlook Therapeutics, Inc. (OTLK)
$0.64-0.03 (-3.90%)
Market ClosedLast close Sep 8
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Outlook Therapeutics, Inc. in the Healthcare sector is trading at $0.64 with a market capitalization of $220M. Wall Street consensus targets $4.90 (4 analysts), implying a +665.0% move over the next 12 months. The stock is currently 75% below its 52-week high of $2.54, remaining 25.5% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +665.0% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $127,439↑ | -$1.21M↓ | -$91,787↓ | $1.51M | $0 |
| Gross Profit | -$21,888↑ | -$1.24M↓ | -$1.01M↓ | $1.07M | $0 |
| Operating Income | -$14.03M↓ | -$13.48M↑ | -$17.31M↓ | -$15.75M↓ | -$12.39M |
| Net Income | -$4.45M↑ | -$23.06M↓ | -$13.29M↑ | -$20.15M↑ | -$46.36M |
Peer Comparison
JNJUNHPFE
Fundamentals
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$219.72M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.80
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
210.23%
Volume
Today's trading volume
4.78M
Recent News
OTLK Q3 Earnings Call Maps LYTENAVA U.S. Launch and Sales Ramp
Outlook Therapeutics targets a year-end 2026 U.S. LYTENAVA launch, with $50M-$75M in first-year net revenues and a ramp tied to reimbursement.
Outlook Therapeutics (OTLK) Stock May Be No Bargain With Approval But Weak Balance Sheet
Outlook Therapeutics stock has been through a very rough stretch over the past few years, and the current checks suggest it still does not screen as a clear bargain despite the recent approval and upcoming launch plans for LYTENAVA. Over the last 5 years, Outlook Therapeutics has delivered a share price decline of about 98%, which shows how much long term holders have seen their investment erode. The planned U.S. commercial launch of FDA approved LYTENAVA, funded in part by a roughly US$55m...
Oncobiologics Q3 Earnings Call Highlights
Oncobiologics (NASDAQ:OTLK) said it is preparing for the U.S. commercial launch of LYTENAVA after the Food and Drug Administration approved the product as the only FDA-approved ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration, or wet AMD, in the United
Outlook Therapeutics, Inc. Q3 2026 Earnings Call Summary
Moby summary of Outlook Therapeutics, Inc.'s Q3 2026 earnings call
Outlook Therapeutics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue Estimates
Outlook Therapeutics, Inc. (OTLK) delivered earnings and revenue surprises of 0.00% and -99.25%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?